Loading...

Author: mitoaction


Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in


Friedreich’s Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research

(COE) at Children’s Hospital of Philadelphia (CHOP) was awarded $1.275 million by the Friedreich’s Read More


Pennington Biomedical to select 375 participants for 2021 research study regarding benefits of exercise

Engaging in regular exercise is typically viewed as a positive activity that results in improved physical and mental health. But, does regular exercise affect some people more positively than...


What does space do to the human body? 29 studies investigate the effects of exploration

INCLUDES EFFECTS ON MITOCHONDRIA: JAXA astronaut Akihiko Hoshide finishes a blood collection as part of Expedition 32 in 2012. With biological data from a whopping 56 astronauts, scientists have...



Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH

NASH/DIABETES 2 RELATED: New results from the Phase 2a STAMP-NAFLD trial show consistently greater response in high-risk patients with coexisting type 2 diabetes (T2DM), estimated to be approximately 50%...


Family’s tribute to ‘handsome and happy’ Charlie, 6, who died from mitochondrial disease

“Always smiling” Charlie Nicholls, aged six, was an inspiration to many people. He tragically died six weeks ago from gut failure, which was secondary to his


Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

RE: DUCHENNES: Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation — — At a total dose exposure approximately 10x lower than eteplirsen,...



Mitochondrial Transplantation to Treat Ischemia-Reperfusion Injury: Interview with Dr. Alexander Schueller, CEO of cellvie

cellvie , a company based in Houston, Texas, is developing a mitochondrial transplantation therapy to help reduce the damage...